Myomo (MYO) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Myomo (NYSEAMERICAN:MYO) from a hold rating to a buy rating in a report released on Thursday. The firm currently has $4.25 price objective on the stock.

According to Zacks, “Myomo, Inc. is a commercial stage medical robotics company. It offers expanded mobility which suffering from neurological disorders and upper limb paralysis. The company develops and markets the MyoPro(R) product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals. Myomo, Inc. is headquartered in Cambridge,Massachusetts. “

How to Become a New Pot Stock Millionaire

A number of other equities analysts have also recently issued reports on MYO. HC Wainwright set a $12.00 target price on Myomo and gave the stock a buy rating in a report on Thursday, March 8th. Roth Capital initiated coverage on Myomo in a report on Friday, March 9th. They set a buy rating and a $9.00 target price for the company.

Shares of Myomo stock opened at $3.33 on Thursday. Myomo has a 1 year low of $2.07 and a 1 year high of $23.20. The company has a market cap of $24.74 and a price-to-earnings ratio of -0.62.

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Myomo during the 4th quarter worth about $124,000. Sequoia Financial Advisors LLC acquired a new position in shares of Myomo during the 4th quarter worth about $257,000. Finally, Hudson Bay Capital Management LP acquired a new position in shares of Myomo during the 4th quarter worth about $294,000.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3298163/myomo-myo-upgraded-at-zacks-investment-research.html.

Myomo Company Profile

Myomo, Inc is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke.

Get a free copy of the Zacks research report on Myomo (MYO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Astro 24-Hour Volume Reaches $3,638.00
Astro 24-Hour Volume Reaches $3,638.00
SyncFab Hits One Day Trading Volume of $45,979.00
SyncFab Hits One Day Trading Volume of $45,979.00
Microsoft Co.  Expected to Post Quarterly Sales of $25.71 Billion
Microsoft Co. Expected to Post Quarterly Sales of $25.71 Billion
Zacks: Analysts Anticipate Shutterstock  Will Announce Quarterly Sales of $150.17 Million
Zacks: Analysts Anticipate Shutterstock Will Announce Quarterly Sales of $150.17 Million
$8.32 Billion in Sales Expected for Enterprise Products  This Quarter
$8.32 Billion in Sales Expected for Enterprise Products This Quarter
Akamai Technologies  Expected to Post Quarterly Sales of $654.02 Million
Akamai Technologies Expected to Post Quarterly Sales of $654.02 Million


© 2006-2018 Ticker Report. Google+.